The US consumer health product sector’s first results from the latest quarter could indicate the start of the strongest period in a decade for OTC cough/cold product sales, analysts at Raymond James suggest.
Increasing numbers for sales of Rx cough/cold drugs combined with an apparent waning interest by consumers in receiving flu vaccines...




